Verona Pharma Plc ADR’s recently made public that its Chief Medical Officer Rickard Kathleen A. unloaded Company’s shares for reported $80503.0 on Feb 05 ’24. In the deal valued at $2.22 per share,36,248 shares were sold. As a result of this transaction, Rickard Kathleen A. now holds 2,731,624 shares worth roughly $42.94 million.
Then, Edwards Martin bought 33,736 shares, generating $61,973 in total proceeds. Upon buying the shares at $1.84, the Director now owns 144,800 shares.
Before that, EBSWORTH DAVID R bought 160,000 shares. Verona Pharma Plc ADR shares valued at $316,080 were divested by the Director at a price of $1.98 per share. As a result of the transaction, EBSWORTH DAVID R now holds 844,643 shares, worth roughly $13.28 million.
Piper Sandler began covering VRNA with “an Overweight” recommendation on August 26, 2022. H.C. Wainwright started covering the stock on September 13, 2021. It rated VRNA as “a Buy”.
Price Performance Review of VRNA
On Friday, Verona Pharma Plc ADR [NASDAQ:VRNA] saw its stock fall -2.36% to $15.72. Over the last five days, the stock has lost -1.19%. Verona Pharma Plc ADR shares have fallen nearly -20.93% since the year began. Nevertheless, the stocks have fallen -29.70% over the past one year. While a 52-week high of $23.81 was reached on 01/04/24, a 52-week low of $11.83 was recorded on 03/20/24. SMA at 50 days reached $16.50, while 200 days put it at $17.01. A total of 0.72 million shares were traded, compared to the trading of 0.49 million shares in the previous session.
Levels Of Support And Resistance For VRNA Stock
The 24-hour chart illustrates a support level at 15.37, which if violated will result in even more drops to 15.01. On the upside, there is a resistance level at 16.14. A further resistance level may holdings at 16.55. The Relative Strength Index (RSI) on the 14-day chart is 42.99, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.07%. Stochastics %K at 31.70% indicates the stock is a holding.
The most recent change occurred on August 25, 2020 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $17 price target.
